Press Releases

Ligand to Webcast Analyst and Investor Day on June 23 in New York City

Twitter Feed on Ligand-Related Events and News to Go Live on May 11th

SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it will hold an Analyst and Investor Day in New York City on Thursday, June 23, 2011. The event will take place at the Andaz 5th Avenue hotel (at 41st Street) from 4:00 p.m. to 6:00 p.m. Eastern time (1:00 p.m. to 3:00 p.m. Pacific time) and will feature presentations around the Company's business and programs. A reception will follow the event from 6:00 p.m. to 7:30 p.m. Eastern time. The event will be webcast live and will be available at www.ligand.com for 30 days following the event for those who can not attend. Invitations and detailed agendas will be sent out shortly.

Ligand on Twitter

Ligand will be launching its own Twitter feed to go live on Wednesday, May 11. Ligand "followers" can expect to see the Company's Twitter feed to include the latest business information, partnership news, links to content published on various Ligand-related topics as well as upcoming Ligand and CyDex events. To become a follower on the Ligand Twitter feed visit http://www.twitter.com/Ligand_LGND or contact Erika Luib at (858) 550-7896 or via e-mail at eluib@ligand.com.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand's goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Bristol-Myers Squibb and AstraZeneca. For more information, please visit www.ligand.com or follow us on http://www.twitter.com/Ligand_LGND.


    Source: Ligand Pharmaceuticals Incorporated